820: Klyushnenkova EN, Riabov VB, Kouiavskaia DV, Wietsma A, Zhan M, Alexander
RB. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential 
for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse
model of prostate cancer. Prostate. 2014 Oct;74(14):1423-32. doi:
10.1002/pros.22858. Epub 2014 Aug 11. PubMed PMID: 25111463.


821: Klyushnenkova EN, Kouiavskaia DV, Parkins CJ, Caposio P, Botto S, Alexander 
RB, Jarvis MA. A cytomegalovirus-based vaccine expressing a single tumor-specific
CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer. J
Immunother. 2012 Jun;35(5):390-9. doi: 10.1097/CJI.0b013e3182585d50. PubMed PMID:
22576344; PubMed Central PMCID: PMC3366429.


822: Klyushnenkova EN, Alexander RB. CD4 T-Cell-mediated immune response to
prostatic proteins in HLA-DRB1*1503 transgenic mice and identification of a novel
HLA-DRB1*1503-restricted T-cell epitope from human prostatic acid phosphatase.
Prostate. 2011 May;71(6):561-6. doi: 10.1002/pros.21271. Epub 2010 Sep 30. PubMed
PMID: 20886538.


823: Klyushnenkova EN, Kouiavskaia DV, Kodak JA, Vandenbark AA, Alexander RB.
Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic
acid phosphatase. Prostate. 2007 Jul 1;67(10):1019-28. PubMed PMID: 17455230.


824: Klyushnenkova EN, Link J, Oberle WT, Kodak J, Rich C, Vandenbark AA,
Alexander RB. Identification of HLA-DRB1*1501-restricted T-cell epitopes from
prostate-specific antigen. Clin Cancer Res. 2005 Apr 15;11(8):2853-61. PubMed
PMID: 15837732.


825: Klyushnenkova EN, Ponniah S, Rodriguez A, Kodak J, Mann DL, Langerman A,
Nishimura MI, Alexander RB. CD4 and CD8 T-lymphocyte recognition of prostate
specific antigen in granulomatous prostatitis. J Immunother. 2004
Mar-Apr;27(2):136-46. PubMed PMID: 14770085.